Literature DB >> 29895074

Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma.

Firuzan Firat Ozer1, Selcuk Dagdelen1, Tomris Erbas1.   

Abstract

The objective of this study was to investigate the effect of hyperprolactinemia and high levels of insulin-like growth factor-I (IGF-I) on bone resorption and their relation with receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) in patients with prolactinoma and acromegaly. Thirty-one patients with acromegaly, 28 patients with prolactinoma, and 33 healthy individuals were included in the study. Serum concentrations of RANKL, OPG, bone alkaline phosphatase (bone ALP), osteocalcin (OC), C-terminal telopeptide of type 1 collagen (CTX), procollagen type 1 N-terminal propeptide (P1NP) and urine deoxypyridinoline (DPD) levels were detected and bone mineral density (BMD) was measured. Groups were not statistically different from each other with regard to serum levels of RANKL and OPG. The RANKL/OPG ratio was higher in the prolactinoma group than in the control group (p=0.046). A positive correlation between OPG and increasing age was detected in both the prolactinoma and control groups (r=0.524, p=0.004 and r=0.380, p=0.029, respectively). An inverse correlation was observed between IGF-I and OPG after excluding age in the prolactinoma group (r=-0.412, p=0.046). OC and bone ALP were negatively associated with RANKL in the acromegaly group (r=-0.384, p=0.036 and r=-0.528, p=0.003, respectively). There was an inverse correlation between OPG and BMD at the femoral neck in the acromegaly group (r=-0.422, p=0.02). The effect of IGF-I on bone remodeling may be partly mediated by RANKL and OPG. The RANKL/OPG ratio plays an important role in prolactinoma. A positive correlation of OPG with age and an inverse correlation with IGF-I favor the compensatory response of OPG against bone loss in the aging skeleton. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29895074     DOI: 10.1055/a-0630-1529

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  7 in total

1.  The tendency of reduced periodontal destruction in acromegalic patients showing similar inflammatory status with periodontitis patients.

Authors:  Yesim Ozdemir; H Gencay Keceli; Nafiye Helvaci; Tomris Erbas; Rahime M Nohutcu
Journal:  Endocrine       Date:  2019-09-02       Impact factor: 3.633

Review 2.  Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Authors:  Cláudia Ribeiro de Moura; Sara Campos Lopes; Ana Margarida Monteiro
Journal:  Pituitary       Date:  2022-07-22       Impact factor: 3.599

3.  Trabecular Bone Score and Osteoprotegerin as Useful Tools in the Assessment of Bone Deterioration in Acromegaly.

Authors:  Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Joanna Syrycka; Agnieszka Zembska; Justyna Kuliczkowska-Płaksej; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-21       Impact factor: 6.055

Review 4.  Hyperprolactinaemia.

Authors:  Irene Samperi; Kirstie Lithgow; Niki Karavitaki
Journal:  J Clin Med       Date:  2019-12-13       Impact factor: 4.241

5.  Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Authors:  Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana
Journal:  Eur J Endocrinol       Date:  2022-02-03       Impact factor: 6.664

6.  Bone biochemical markers in acromegaly: An association with disease activity and gonadal status.

Authors:  Mehmet Emin Piskinpasa; Hamide Piskinpasa
Journal:  North Clin Istanb       Date:  2022-02-10

7.  The role of WNT1 mutant variant (WNT1c.677C>T ) in osteogenesis imperfecta.

Authors:  Bashan Zhang; Rong Li; Wenfeng Wang; Xueming Zhou; Beijing Luo; Zinian Zhu; Xibo Zhang; Aijiao Ding
Journal:  Ann Hum Genet       Date:  2020-08-05       Impact factor: 1.670

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.